FDA scraps AdComm for Reata's rare disease candidate, leaving analysts squinting at the tea leaves

The omaveloxolone saga has delivered yet another twist. Having previously put an advisory committee meeting on hold, the FDA has now scrapped plans to convene experts to discuss Reata Pharmaceuticals’ candidate altogether, leaving analysts to argue over whether the change is a good or bad omen.